Detected on Tuesday 17 November, 19h00
Sanofi relocates production of type 1 diabetes treatment to Lyon
Sanofi has transferred to France, at its Lyon Gerland site, the production of a biotherapy for type 1 diabetes acquired from the United States in 2023. The group presents this relocation as a commitment to health sovereignty.
In brief
Economy event (severity: notable) in Lyon Gerland (Rhône), first detected on 17 November 2026 at 19:00. Reported by 1 source (1 article), last updated on 17 November 2026 at 19:00.
1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 1, right 0
Angle comparison
A comparison is written as soon as the event is covered by at least two sides (left, centre, right).
Lire les sources · 1 article, 1 source
- 19h00Le ProgrèsCentreWire17 NovSanté. Comment Sanofi a relocalisé un médicament contre le diabète à Lyon
En 2023, Sanofi a acquis aux États-Unis le premier traitement capable de retarder l’apparition au stade clinique du diabète de type 1. Le géant pharmaceutique a alors décidé de transférer en France, sur son site de Lyon Gerland, la production de cette biothérapie. Une illustration de l’engagement de Sanofi en faveur de la souveraineté sanitaire, expliquent ses responsables.
Further reading
Organisations cited
Places cited
Keywords
#Sanofi · #relocalisation · #diabète
Go up the thread
Affected departments
People and organisations cited